ICU Medical (NASDAQ:ICUI) VP Virginia Ruth Sanzone Sells 4,856 Shares of Stock

Key Points

• ICU Medical VP Virginia Sanzone sold 4,856 shares for approximately $819,159 under a pre-arranged Rule 10b5-1 trading plan, reducing her direct holdings by 24.95% to 14,604 shares.
• ICU Medical shares fell 2.1% to $166.29, while the company reported quarterly EPS of $2.37 and revenue of $547.88 million, beating analyst expectations.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and a $192.80 price target; institutional investors own 96.1% of the stock.

ICU Medical, Inc. (NASDAQ:ICUI - Get Free Report) VP Virginia Sanzone sold 4,856 shares of the business's stock in a transaction on Thursday, September 3rd. The stock was sold at an average price of $168.69, for a total transaction of $819,158.64. Following the completion of the sale, the vice president directly owned 14,604 shares in the company, valued at approximately $2,463,548.76. This represents a 24.95% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ICU Medical Trading Down 2.1%

NASDAQ ICUI traded down $3.56 on Thursday, reaching $166.29. The company had a trading volume of 241,539 shares, compared to its average volume of 290,811. The firm has a market cap of $4.16 billion, a price-to-earnings ratio of 140.92, a P/E/G ratio of 2.16 and a beta of 0.75. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.43 and a quick ratio of 1.21. ICU Medical, Inc. has a fifty-two week low of $112.50 and a fifty-two week high of $192.85. The business has a 50 day moving average of $166.61 and a two-hundred day moving average of $144.55.

ICU Medical (NASDAQ:ICUI - Get Free Report) last announced its earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $1.91 by $0.46. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The firm had revenue of $547.88 million for the quarter, compared to the consensus estimate of $533.44 million. During the same period in the previous year, the business earned $2.10 EPS. The business's quarterly revenue was up .5% compared to the same quarter last year. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. Analysts forecast that ICU Medical, Inc. will post 7.19 EPS for the current year.

Institutional Investors Weigh In On ICU Medical

A number of large investors have recently bought and sold shares of ICUI. Allworth Financial LP acquired a new position in shares of ICU Medical during the second quarter valued at about $26,000. Hilton Head Capital Partners LLC acquired a new stake in shares of ICU Medical in the 4th quarter valued at about $32,000. Public Employees Retirement System of Ohio acquired a new stake in shares of ICU Medical in the 2nd quarter valued at about $51,000. Covestor Ltd increased its position in ICU Medical by 22.1% in the 4th quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier's stock valued at $99,000 after buying an additional 126 shares in the last quarter. Finally, Strs Ohio increased its position in ICU Medical by 60.0% in the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier's stock valued at $114,000 after buying an additional 300 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Zacks Research cut ICU Medical from a "strong-buy" rating to a "hold" rating in a report on Tuesday, July 28th. Piper Sandler raised their price target on shares of ICU Medical from $163.00 to $195.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. KeyCorp boosted their price target on shares of ICU Medical from $164.00 to $182.00 and gave the stock an "overweight" rating in a research report on Tuesday, July 21st. BTIG Research boosted their price target on shares of ICU Medical from $170.00 to $200.00 and gave the stock a "buy" rating in a research report on Friday, August 7th. Finally, Wall Street Zen raised shares of ICU Medical from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $192.80.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source